盐酸表柔比星联合卡培他滨片治疗三阴性乳腺癌的临床疗效及对血清相关指标水平变化
|
摘要
目的比较三阴性乳腺癌患者应用盐酸表柔比星和卡培他滨片联合治疗的临床疗效和对血清相关指标水平的影响。方法分析该院于2016年12月—2017年12月收治的96例三阴性乳腺癌患者资料,按照不同治疗方案分成两组,将行盐酸表柔比星单纯治疗48例患者作为对照组,将和卡培他滨片联合治疗48例患者作为观察组,比较两组临床疗效和血清相关指标水平。结果观察组总有效率83.33%比对照组45.83%高,且血管内皮生长因子-C、血清骨桥蛋白水平(5.11±0.04)μg/mL、(580.40±71.06)pg/mL均比对照组优(P<0.05);观察组总不良反应率8.33%比对照组25.00%低(P<0.05)。结论三阴性乳腺癌患者应用盐酸表柔比星和卡培他滨片联合治疗能够改善临床症状,优化血清指标,且安全性较高,具较高推广价值。
Objective To compare the curative effect of epirubicin hydrochloride combined with capecitabine tablets in treatment of triple negative breast cancer and effect on the changes of level of serum related indicators. Methods 96 cases of patients with triple negative breast cancer admitted and treated in our hospital from December 2016 to December 2017 were selected and divided into two groups according to different treatment plans, with 48 cases in each, the control group were treated with single capecitabine tablets, while the observation group were treated with epirubicin hydrochloride combined with capecitabine tablets, and the clinical curative effect and serum related indicators were compared between the two groups. Results The total effective rate in the observation group was higher than that in the control group(83.33% vs 45.83%), and the vascular endothelial growth factor-C and serum osteopontin in the observation group were respectively(5.11±0.04)μg/L,(580.40±71.06)pg/mL, which were better than those in the control group(P<0.05), and the total adverse reaction rate in the observation group was lower than that in the control group(8.33% vs 25.00%)(P<0.05). Conclusion The epirubicin hydrochloride combined with capecitabine tablets in treatment of triple negative breast cancer can improve the clinical symptoms, and optimize the serum indicators, with high safety, which is of higher promotion value.
Objective To compare the curative effect of epirubicin hydrochloride combined with capecitabine tablets in treatment of triple negative breast cancer and effect on the changes of level of serum related indicators. Methods 96 cases of patients with triple negative breast cancer admitted and treated in our hospital from December 2016 to December 2017 were selected and divided into two groups according to different treatment plans, with 48 cases in each, the control group were treated with single capecitabine tablets, while the observation group were treated with epirubicin hydrochloride combined with capecitabine tablets, and the clinical curative effect and serum related indicators were compared between the two groups. Results The total effective rate in the observation group was higher than that in the control group(83.33% vs 45.83%), and the vascular endothelial growth factor-C and serum osteopontin in the observation group were respectively(5.11±0.04)μg/L,(580.40±71.06)pg/mL, which were better than those in the control group(P<0.05), and the total adverse reaction rate in the observation group was lower than that in the control group(8.33% vs 25.00%)(P<0.05). Conclusion The epirubicin hydrochloride combined with capecitabine tablets in treatment of triple negative breast cancer can improve the clinical symptoms, and optimize the serum indicators, with high safety, which is of higher promotion value.
引文
[1]周儒兵,李伟,周双容.多西他赛注射剂联合吡柔比星注射剂治疗乳腺癌的临床研究[J].中国临床药理学杂志,2017,33(13):1194-1197.
[2]杨庄青,邹天宁,刘德权,等.表柔比星联合紫杉醇治疗三阴性乳腺癌的效果分析[J].中国生化药物杂志,2014,34(6):113-115.
[3]朱德淼,李锦成.TP新辅助方案治疗三阴性乳腺癌疗效的临床研究[J].医学与哲学,2015,36(8):31-33,63.
[4]李俏,徐兵河,李青,等.顺铂联合卡培他滨治疗蒽环和紫杉类耐药晚期三阴性乳腺癌的近期疗效与安全性[J].中华肿瘤杂志,2015,37(12):938-941.
[5]李继恩,王旭东,姜在鹏,等.替吉奥口服联合三维适形放疗治疗三阴性乳腺癌效果观察[J].山东医药,2016,56(18):45-47.
[6]王晓蕊,汪旭,史业辉,等.阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效观察[J].中国肿瘤临床,2017,44(15):769-772.
[7]王征,翟晓建,叶新平,等.细胞免疫在三阴性乳腺癌治疗中的临床研究[J].重庆医学,2014,43(15):1937-1939.
[8]吴开林,林龙,赵国栋.表柔比星联合紫杉醇治疗三阴性乳腺癌的效果分析[J].实用临床医药杂志,2017,21(15):165-167.
[9]洪伟,李福广,王治伟,等.卡培他滨联合表阿霉素治疗晚期三阴性乳腺癌的临床效果及其对血管内皮生长因子-C的影响[J].疑难病杂志,2016,15(6):610-613.
[10]罗莉,唐东昕,王定雪,等.表柔比星联合卡培他滨治疗三阴性乳腺癌的疗效及安全性分析[J].中国生化药物杂志,2015,35(9):138-140.
[11]李林,王楠,秦威,等.卡培他滨对复发转移三阴性乳腺癌患者的治疗作用[J].中华实验外科杂志,2017,34(9):1552-1554.
[12]罗宁,武菲菲.表柔比星联合紫杉醇治疗三阴性乳腺癌效果分析[J].中国生化药物杂志,2017,37(7):180-181.
[13]李剑英,季从飞,陈佳,等.卡培他滨维持治疗晚期乳腺癌的临床观察[J].中国癌症杂志,2014,24(5):381-386.
[2]杨庄青,邹天宁,刘德权,等.表柔比星联合紫杉醇治疗三阴性乳腺癌的效果分析[J].中国生化药物杂志,2014,34(6):113-115.
[3]朱德淼,李锦成.TP新辅助方案治疗三阴性乳腺癌疗效的临床研究[J].医学与哲学,2015,36(8):31-33,63.
[4]李俏,徐兵河,李青,等.顺铂联合卡培他滨治疗蒽环和紫杉类耐药晚期三阴性乳腺癌的近期疗效与安全性[J].中华肿瘤杂志,2015,37(12):938-941.
[5]李继恩,王旭东,姜在鹏,等.替吉奥口服联合三维适形放疗治疗三阴性乳腺癌效果观察[J].山东医药,2016,56(18):45-47.
[6]王晓蕊,汪旭,史业辉,等.阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效观察[J].中国肿瘤临床,2017,44(15):769-772.
[7]王征,翟晓建,叶新平,等.细胞免疫在三阴性乳腺癌治疗中的临床研究[J].重庆医学,2014,43(15):1937-1939.
[8]吴开林,林龙,赵国栋.表柔比星联合紫杉醇治疗三阴性乳腺癌的效果分析[J].实用临床医药杂志,2017,21(15):165-167.
[9]洪伟,李福广,王治伟,等.卡培他滨联合表阿霉素治疗晚期三阴性乳腺癌的临床效果及其对血管内皮生长因子-C的影响[J].疑难病杂志,2016,15(6):610-613.
[10]罗莉,唐东昕,王定雪,等.表柔比星联合卡培他滨治疗三阴性乳腺癌的疗效及安全性分析[J].中国生化药物杂志,2015,35(9):138-140.
[11]李林,王楠,秦威,等.卡培他滨对复发转移三阴性乳腺癌患者的治疗作用[J].中华实验外科杂志,2017,34(9):1552-1554.
[12]罗宁,武菲菲.表柔比星联合紫杉醇治疗三阴性乳腺癌效果分析[J].中国生化药物杂志,2017,37(7):180-181.
[13]李剑英,季从飞,陈佳,等.卡培他滨维持治疗晚期乳腺癌的临床观察[J].中国癌症杂志,2014,24(5):381-386.